Vidyya Medical News Service
*
Volume 7 Issue 87 Published - 14:00 UTC 08:00 EST 28-Mar-2005 Next Update - 14:00 UTC 08:00 EST 29-Mar-2005
little clear gif used for spacer
.
*

Beating the odds on heart disease: when it comes to living longer, staying active is key
Two studies in the April issue of Diabetes Care add to a growing body of evidence that keeping physically active is a very important thing a person can do to reduce his or her chances of dying from heart disease -- even if they can't shake problems such as high blood pressure, obesity or high cholesterol.  more

*
New estimates for the causes of child deaths worldwide
The most accurate estimates of the causes of child deaths to date, published in this week’s issue of The Lancet, reveal that worldwide more than 70% of the 10·6 million child deaths that occur annually are attributable to six causes: pneumonia (19%), diarrhoea (18%), malaria (8%), neonatal sepsis or pneumonia (10%), preterm delivery (10%), and asphyxia at birth (8%).  more

*
Deficiency of growth hormone and igf-1 reduces cancer and kidney disease
Deficiencies of growth hormone and similar compounds may reduce cancer and kidney disease late in life, but also may lead to cartilage degeneration and impaired memory and learning ability, according to research at Wake Forest University Baptist Medical Center and four other institutions. more

 


*
Cultural and social factors influence prostate cancer treatment
Researchers say social and cultural factors play a significant role in patients' prostate cancer treatment decisions. A new study published in the 1 May 2005 issue of CANCER finds non-medical variables, such as marital status, high school education, and race/ethnicity may play a larger role in patients' treatment decisions than previously believed.  more

*
Lack of clinical trial participation may contribute to lower survival rates
A new study finds poor survival rates among young adults and older adolescents with some cancers may be partially explained by the lack of participation in clinical trials. The study, published in the 1 May 2005 issue of Cancer, found that age-dependent survival rates among patients with sarcomas - except Kaposi Sarcoma (KS) - correlated with clinical trial participation rates.  more

*
FDA grants full approval for Velcade(R) (bortezomib) for injection; claims include survival advantage and use in second-line multiple myeloma
Millennium Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) approved the Company's supplemental New Drug Application (sNDA) for VELCADE. This approval expands the label to include the treatment of patients with multiple myeloma (MM) who have received at least one prior therapy. VELCADE is the only drug therapy that has demonstrated a significant survival advantage as compared to a standard therapy in relapsed MM. Initial accelerated approval for relapsed and refractory MM was granted in May 2003. VELCADE is now fully approved in relapsed MM.  more

*
FDA approves once-monthly Boniva(R) for osteoporosis first-ever monthly single tablet for any disease
The U.S. Food and Drug Administration (FDA) today approved once- monthly oral Boniva(R) (ibandronate sodium) 150 mg Tablets, the first and only once-a-month medicine for the treatment of postmenopausal osteoporosis, Roche and GlaxoSmithKline (GSK) announced.  more

 
little clear gif used for a space